Characterization of active and inactive states of CB1 receptor and the differential binding state modulation by cannabinoid agonists, antagonists and inverse agonists

Neuropharmacology

Volumn 58, Issue 8, 2010, Pages 1215-1219

  Gullapalli, Srinivas ^a   Amrutkar, Dipak ^a   Gupta, Sangeetha ^a   Kandadi, Machender R ^a   Kumar, Hemant ^a   Gandhi, Maulik ^a   Karande, Vikas ^a,b   Narayanan, Shridhar ^a,c  

^a Glenmark Pharmaceuticals Limited   (India)

^b Advinus Therapeutics Private Limited Bangalore   (India)

^c Orchid Research Laboratories Ltd   (India)

Author keywords

Active R* state; CB1 receptors; Competitive binding; Gpp(NH)p; Inactive R state; Saturation binding

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID 1 RECEPTOR; RIMONABANT; TRITIUM;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN MEMBRANE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOG; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; LIGAND BINDING; MALE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAT;

ANIMALS; BINDING, COMPETITIVE; BRAIN; CYCLOHEXANOLS; DOGS; DRUG INVERSE AGONISM; LIGANDS; PIPERIDINES; PROTEIN BINDING; PYRAZOLES; RADIOLIGAND ASSAY; RATS; RECEPTOR, CANNABINOID, CB1;

EID: 77952883962     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.03.001     Document Type: Article

References (36)

1. Addy C., Wright H., Van Laere K., Gantz I., Erondu N., Musser B.J., Lu K., Yuan J., Sanabria-Bohorquez S.M., Stoch A., Stevens C., Fong T.M., De Lepeleire I., Cilissen C., Cote J., Rosko K., Gendrano I.N., Nguyen A.M., Gumbiner B., Rothenberg P., de Hoon J., Bormans G., Depre M., Eng W., Ravussin E., Klein S., Blundell J., Herman G.A., Burns H.D., Hargreaves R.J., Wagner J., Gottesdiener K., Amatruda J.M., Heymsfield S.B. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell. Metab. 2008, 7(1):68-78.
2. Bouaboula M., Perrachon S., Milligan L., Canat X., Rinaldi-Carmona M., Portier M., Barth F., Calandra B., Pecceu F., Lupker J., Maffrand J.P., Le Fur G., Casellas P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 1997, 272(35):22330-22339.
3. Bylund D.B., Toews M.L. Radioligand binding methods: practical guide and tips. Am. J. Physiol. 1993, 265(5):L421-L429.
4. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22(23):3099-3108.
5. Chidiac P., Hebert T.E., Valiquette M., Dennis M., Bouvier M. Inverse agonist activity of beta-adrenergic antagonists. Mol. Pharmacol. 1994, 45(3):490-499.
6. Costa T., Ogino Y., Munson P.J., Onaran H.O., Rodbard D. Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol. Pharmacol. 1992, 41(3):549-560.
7. De Lean A., Stadel J.M., Lefkowitz R.J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J. Biol. Chem. 1980, 255(15):7108-7117.
8. Despres J.P., Golay A., Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 2005, 353(20):2121-2134.
9. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 1988, 34(5):605-613.
10. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., Mitchell R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 1995, 48(3):443-450.
11. Gatley S.J., Lan R., Pyatt B., Gifford A.N., Volkow N.D., Makriyannis A. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci. 1997, 61(14):191-197. PL.
12. Gerard C.M., Mollereau C., Vassart G., Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J. 1991, 279(Pt 1):129-134.
13. 3 Adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. Mol. Pharmacol. 2002, 61(2):415-424.
14. Gullapalli, S., Muthuppalaniappan, M., Thomas, A., Khairatkar-Joshi, N., Varanasi, K., Vakkalanka, S.K.V.S., Narayanan, S., 2006. Novel orally active CB2 receptor agonists with potential anti-hyperalgesic effects. 16th Annual Symposium of International Cannabinoid Research Society (ICRS), June 25-28, Tihany, Hungary, Abstract # 130, page 158.
15. Gullapalli S., Ramarao P. L-type Ca2+ channel modulation by dihydropyridines potentiates kappa-opioid receptor agonist induced acute analgesia and inhibits development of tolerance in rats. Neuropharmacology 2002, 42(4):467-475.
16. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U. S. A. 1990, 87(5):1932-1936.
17. Howlett A.C., Johnson M.R., Melvin L.S., Milne G.M. Nonclassical cannabinoid analgesics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol. Pharmacol. 1988, 33(3):297-302.
18. Kearn C.S., Greenberg M.J., DiCamelli R., Kurzawa K., Hillard C.J. Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J. Neurochem. 1999, 72(6):2379-2387.
19. 1 cannabinoid receptors be selectively targeted for therapeutic gain?. Trends Pharmacol. Sci. 2009, 30(1):1-7.
20. Lange J.H., Coolen H.K., van Stuivenberg H.H., Dijksman J.A., Herremans A.H., Ronken E., Keizer H.G., Tipker K., McCreary A.C., Veerman W., Wals H.C., Stork B., Verveer P.C., den Hartog A.P., de Jong N.M., Adolfs T.J., Hoogendoorn J., Kruse C.G. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J. Med. Chem. 2004, 47(3):627-643.
21. Leff P. The two-state model of receptor activation. Trends Pharmacol. Sci. 1995, 16(3):89-97.
22. Lefkowitz R.J., Cotecchia S., Samama P., Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 1993, 14(8):303-307.
23. Lewis D.L. Cannabinoid receptor G protein-coupling and inverse agonism. Curr. Neuropharmacol. 2004, 2:31-36.
24. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193(1):265-275.
25. Mackie K., Lai Y., Westenbroek R., Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 1995, 15(10):6552-6561.
26. Merighi S., Simioni C., Gessi S., Varani K., Borea P.A. Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors. Biochem. Pharmacol. 2010, 79(3):471-477.
27. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346(6284):561-564.
28. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365(6441):61-65.
29. Narayanan, S., Thomas, A., Chaudhari, S., Khairatkar-Joshi, N., Karnik, P., Raghuram, A., Gullapalli, S., Varanasi, K., Vakkalanka, S.K.V.S., 2006. GRC 10389AA: A novel orally active CB-1 antagonist for the treatment of obesity. European Winter Congress on Brain Research (EWCBR), March 6-10, Villars Surollon, Switzerland (). http://www.asso.univ-paris5.fr/ewcbr/Francais/EWCBR2006/Abstracts2006/Narayanan.pdf.
30. Pan X., Ikeda S.R., Lewis D.L. Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system. Mol. Pharmacol. 1996, 49(4):707-714.
31. Pavon F.J., Serrano A., Perez-Valero V., Jagerovic N., Hernandez-Folgado L., Bermudez-Silva F.J., Macias M., Goya P., de Fonseca F.R. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J. Neuroendocrinol. 2008, 20(Suppl. 1):116-123.
32. Pertwee R.G. The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obes. (Lond) 2006, 30(Suppl. 1):S13-S18.
33. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994, 350(2-3):240-244.
34. Scheen A.J., Finer N., Hollander P., Jensen M.D., Van Gaal L.F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368(9548):1660-1672.
35. Seifert R., Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn. Schmiedebergs Arch. Pharmacol. 2002, 366(5):381-416.
36. Thomas B.F., Gilliam A.F., Burch D.F., Roche M.J., Seltzman H.H. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J. Pharmacol. Exp. Ther. 1998, 285(1):285-292.